StocksMedium•9 November 2026•
1 min read
Lisata Subsidiary Marea Announces Positive Phase 2b Results for MAR001
Key Facts
1The Phase 2b TYDAL-TIMI 78 trial achieved significant triglyceride reductions of up to 45.5% without worsening glycemic control.
Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced positive Phase 2b results for its MAR001 drug candidate from the TYDAL-TIMI 78 trial. GlobeNewswire reported that the trial achieved significant triglyceride reductions of up to 45.5% and met all primary objectives across all doses without worsening glycemic control.
LSTA closed at $1.03 on November 6, 2026, with the stock trading between a low of $0.99 and a high of $1.06 during that session. These clinical findings, which were published in the New England Journal of Medicine, support the development of the therapy targeting the ANGPTL4 protein.